ImmBio Wins Technology Strategy Board Award to develop a vaccine against invasive meningococcal disease
ImmBio Wins Technology Strategy Board Award to develop a vaccine against invasive meningococcal disease... Read more
ImmBio Wins Technology Strategy Board Award to develop a vaccine against invasive meningococcal disease... Read more
John Lambert Appointed as Chairman of the Board of ImmunoBiology Ltd (“ImmBio” Cambridge, UK... Read more
ImmunoBiology Ltd ("ImmBio") is pleased to announce that it has closed a new round of finance, raising £3.0m... Read more
ImmunoBiology Ltd, a vaccine development company based at the Babraham Research Campus near Cambridge UK, is pleased to announce the signing of an initial cooperation agreement with LIBP... Read more
The bacterium Clostidium difficile (“C. difficile”) is likely to remain a healthcare issue due to difficulties in preventing infection and its life-threatening consequences... Read more
Preventing meningitis is a major healthcare goal. Infection is rapid but early detection is difficult, by which time the impact can include disability due to damage to the brain, surrounded by the meninges, through to death... Read more